-
Watson, Natco ink deal for generic Revlimid
MORRISTOWN, N.J. — U.S. generic drug maker Watson Pharmaceuticals and Indian drug maker Natco Pharma will work together to develop and commercialize a generic drug used for bone marrow disorders, the two companies said Tuesday.
The agreement concerns lenalidomide tablets in the 5-mg, 10-mg, 15-mg and 25-mg strengths. The drug is a generic version of Celgene’s Revlimid, used to treat the plasma cell cancer multiple myeloma and myelodysplastic syndrome. Myelodysplastic syndrome results from the bone marrow producing blood cells that are misshapen.